Epidermal Growth Factor Receptor Status and the Response of Bladder Carcinoma Cells to Erlotinib

Journal of Urology

Volumn 178, Issue 4, 2007, Pages 1510-1514

  Jacobs, Micah A ^a   Wotkowicz, Chad ^a   Baumgart, Egbert D ^a   Neto, Brasil Silva ^a   Rieger Christ, Kimberly M ^a   Bernier, Trisha ^a   Cohen, Michael S ^a   Libertino, John A ^a   Summerhayes, Ian C ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

bladder; bladder neoplasms; epidermal growth factor; erlotinib; mutation; receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT3 PROTEIN;

ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER INHIBITION; CONCENTRATION RESPONSE; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; EXON; HUMAN; HUMAN CELL; MESENCHYME CELL; MUTATION RATE; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR UPREGULATION; SINGLE STRAND CONFORMATION POLYMORPHISM;

BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXONS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR; TUMOR STEM CELL ASSAY; URINARY BLADDER NEOPLASMS;

EID: 34548458554     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.05.113     Document Type: Article

References (20)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics. CA Cancer J Clin 56 (2006) 106
2. Wu X.R. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5 (2005) 713
3. Thogersen V.B., Jorgensen P.E., Sorensen B.S., Bross P., Orntoft T., Wolf H., et al. Expression of transforming growth factor alpha and epidermal growth factor receptor in human bladder cancer. Scand J Clin Lab Invest 59 (1999) 267
4. Popov Z., Gil-Diez-De-Medina S., Ravery V., Hoznek A., Batsuji-Garin S., Lefrere-Belda M.A., et al. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol 22 (2004) 93
5. Cheng J., Huang H., Zhang Z.T., Shapiro E., Pellicer A., Sun T.T., et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res 62 (2002) 4157
6. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129
7. Yang S.H., Mechanic Le., Yang P., Landi M.T., Bowman E.D., Wampfler J., et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small lung cancer. Clin Cancer Res 11 (2005) 2106
8. Marchetti A., Martella C., Felicioni L., Barassi F., Salvatore S., Cehlla A., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23 (2005) 857
9. Taron M., Ichinose Y., Rosell R., Mok T., Massuti B., Zamora L., et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in the gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11 (2005) 5878
10. Frederick L., Wang X.Y., Eley G., and James C.D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60 (2000) 1383
11. Nagahara H., Mimori K., Ohta M., Utsunomiya T., Inoue H., Barnard G.F., et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 11 (2005) 1368
12. Lee J.W., Soung Y.H., Kim S.Y., Nam H.K., Park W.S., Nam S.W., et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11 (2005) 2879
13. Nutt J.E., Lazarowicz H.P., Mellon J.K., and Lunec J. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumor cell lines to epidermal growth factor and induces TIMP2. Br J Cancer 90 (2004) 1679
14. Maddineni S.B., Sangar V.K., Hendry J.H., Margison G.P., and Clarke N.W. Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines. Br J Cancer 92 (2005) 125
15. Kawamata H., Hattori K., Omotehara F., Uchida D., Hino S., Sato M., et al. Balance between activated-STAT and MAP kinase regulates the growth of human bladder cell lines after treatment with epidermal growth factor. Int J Oncol 15 (1999) 661
16. Blehm K.N., Speiss P.E., Bondaruk J.E., Dujka M.E., Villares G.J., Zhao Y.J., et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: Implications for therapy. Clin Cancer Res 12 (2006) 4671
17. Nicolle G., Daher A., Maille P., Vermey M., Loric S., Bakkar A., et al. Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation. Clin Cancer Res 12 (2006) 2937
18. Thomson S., Buck E., Petti F., Griffin G., Brown E., Ramnarine N., et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibitions. Cancer Res 65 (2005) 9455
19. Baumgart E., Cohen M.S., Neto B.S., Jacobs M.A., Wotkowicz C., Rieger-Christ K.M., et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 13 (2007) 1685
20. Kassouf W., Dinney C.P.N., Brown G., McConkey D.J., Diehl A.J., Bar-Eli M., et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib. Cancer Res 65 (2005) 10524